Omega Diagnostics Group PLC Directorate Change (9840J)
22 Agosto 2023 - 3:00AM
UK Regulatory
TIDMODX
RNS Number : 9840J
Omega Diagnostics Group PLC
22 August 2023
OMEGA DIAGNOSTICS GROUP PLC
("Omega", the "Company" or the "Group")
Directorate Change
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Health and Nutrition products,
announces that Chris Lea, Group Finance Director of the Company,
will be stepping down as a Director and leaving the Company with
immediate effect.
Chris has been instrumental in selling the Alva site and
subsequent sale of the CD4 Business along with a restructuring of
Omega, based in Ely, Cambridgeshire . The restructuring and
disposals were key in refocusing the Company on food intolerance
testing and ensuring it has sufficient resources to drive Omega
forward. Chris is based in Scotland and his stepping down is in
line with the Company strategy to focus more of its resources in
and around the Company's headquarters in Ely, Cambridge.
As per the recent results, the Company remains very well-funded
with GBP5.1m of cash at 31 March 2023. This is more than sufficient
to build on the platform Omega has to drive a profitable and
sustainable Company.
Omega intends to change its name to Cambridge Nutritional
Sciences at the upcoming Annual General Meeting and intends to
appoint an interim CFO shortly.
Simon Douglas, Chairman of Omega, said: "We thank Chris for all
his efforts and fully appreciate how instrumental he was in the
refocusing and restructuring of the Company. We wish him all the
best for the future."
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Jag Grewal, Chief Executive Officer via Walbrook PR
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore (Corporate
Finance)
Nigel Birks/Harriet Ward (ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 85 countries and is now focused on
the health and nutrition sector. www.omegadx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUPWRUPWGQG
(END) Dow Jones Newswires
August 22, 2023 02:00 ET (06:00 GMT)
Omega Diagnostics (LSE:ODX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Omega Diagnostics (LSE:ODX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025